Last reviewed: June 6, 2026
Last updated: June 6, 2026
Written by:
Jay Hastings,
CEO of PlexusDx
Jay Hastings is the CEO of PlexusDx, a precision health company focused on genetic testing, blood biomarker insights, and personalized wellness recommendations. He has more than 20 years of experience across healthcare innovation, genomics, laboratory operations, healthcare investing, and strategic finance.
Medically reviewed by:
Jayden Lee, PharmD, EMBA
Jayden Lee, PharmD, EMBA, is the PlexusDx Medical Science Liaison with a PharmD and MBA specializing in pharmacogenomics and clinical product development, with a proven ability to bridge the gap between genomic research and practical patient outcomes. Dr. Lee has more than 10 years of professional experience in clinical pharmacy, academia, and research.
This article is part of the PlexusDx Education Hub — science-backed guidance on GLP-1 medications, metabolic health, and precision weight management.
Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has become one of the most prescribed medications for weight management, with studies showing an average weight loss of 15–22% over one year. However, not every person is a candidate for this therapy, and understanding your eligibility—along with your unique metabolic genetics—is essential before starting treatment. PlexusDx helps patients access compounded semaglutide from licensed pharmacies while identifying which peptide pathways matter most for your weight loss success.
Medical Eligibility for Semaglutide Weight Loss
Semaglutide is approved for weight loss in adults with a body mass index (BMI) of 27 or higher who also have at least one weight-related health condition, or a BMI of 30 or higher regardless of other conditions. However, PlexusDx-prescribed compounded semaglutide serves a broader patient population beyond FDA-labeled indications, offering personalized dosing for those who meet clinical criteria established through medical evaluation. Your healthcare provider will assess your metabolic history, current medications, and weight loss goals to determine if semaglutide is appropriate for your situation.
Patients with a personal or family history of medullary thyroid cancer or multiple endocrine neoplasia type 2 (MEN2) should not use semaglutide, as the drug carries a black-box warning for these populations. Pregnancy and breastfeeding are also contraindications, and anyone with severe gastroparesis or pancreatitis history requires careful medical review. PlexusDx's medical intake process screens for these critical exclusions before your first dose.
How Semaglutide Works for Weight Management
Semaglutide mimics the GLP-1 hormone, which regulates appetite, blood sugar, and how quickly your stomach empties after eating. When you activate GLP-1 receptors in the brain, your hunger signals decrease, your sense of fullness arrives sooner, and food cravings—particularly for high-calorie or sugary foods—often fade within days to weeks. This dual mechanism of reduced hunger plus improved satiety makes semaglutide effective for people whose weight struggles are driven by appetite dysregulation rather than lack of willpower.
The medication also slows gastric transit, meaning food stays in your stomach longer, which reinforces the feeling of fullness with smaller meal portions. Over time, many patients naturally eat 500–1,000 fewer calories per day without restriction dieting, making sustainable weight loss feel less like deprivation. Response varies by individual genetics and metabolic profile, which is why PlexusDx offers the Precision Peptide Genetic Test to map your GLP1R and GIPR variants, helping predict your likely response to semaglutide therapy.
Common Medical Conditions That Require Screening
People with type 2 diabetes, prediabetes, or metabolic syndrome are often excellent candidates for semaglutide, since the medication improves blood sugar control alongside weight loss. However, those already taking insulin or other diabetes drugs may need dose adjustments to prevent low blood sugar (hypoglycemia), so medical supervision is critical. PlexusDx requires a baseline health intake and ongoing provider communication to monitor these interactions.
Patients with a history of pancreatitis, gallbladder disease, or severe kidney or liver impairment should discuss semaglutide use carefully with their provider, as these conditions may affect dosing safety or tolerability. Thyroid disease that is well-controlled is not a contraindication, but ongoing thyroid monitoring is recommended during weight loss, since rapid weight reduction can shift thyroid hormone needs. Anyone on blood pressure or cholesterol medications should expect potential downward dose adjustments as weight decreases and metabolic markers improve.
Age, Pregnancy, and Special Populations
Semaglutide is approved for weight loss in adults 18 and older; it is not recommended for adolescents under age 18 for weight loss, though some medical centers use it off-label for severe pediatric obesity. Adults over 65 can use semaglutide safely, though dose titration may be slower and side effect monitoring more frequent. Pregnant or nursing patients must discontinue semaglutide at least two months before attempting conception, as animal studies suggest potential fetal effects; this timeline gives the medication time to clear your system.
People with a history of suicidal ideation or severe depression should inform their healthcare provider before starting semaglutide, since GLP-1 drugs are occasionally associated with mood changes in rare cases. Those with a personal or close family history of medullary thyroid cancer or MEN2 syndrome are absolute contraindications and should never use GLP-1 receptor agonists. PlexusDx screens all these risk factors during medical intake to ensure safe, appropriate matching with therapy.
How Your Genetics Influence GLP-1 Response
Not everyone responds to GLP-1 medications the same way. Genetic variants — including GIPR rs1800437, GLP1R rs6923761, FTO rs9939609, and MC4R rs17782313 — influence how your body processes these medications, how much weight you lose, and how you tolerate side effects. PlexusDx maps 14 pathways, 49 peptides, and 150+ genetic insights to match each patient to the right medication, dose, and lifestyle protocol for their biology. The PlexusDx Precision Peptide Genetic Test ($99 add-on after your first month of treatment) gives your provider precise insight into your peptide genetic predispositions before the first prescription is written.
Access Personalized GLP-1 Care Through PlexusDx
PlexusDx offers six prescription GLP-1 protocols to all 50 states — no membership, no insurance required, async intake or live consult. The Semaglutide Injection starts at $149/mo. Medications are dispensed from licensed 503A compounding pharmacies following strict quality and safety standards. Add a Precision Peptide Genetic Test for $99 to personalize your protocol from day one.
Frequently Asked Questions
Do I need to be overweight to qualify for semaglutide with PlexusDx?
No. While FDA-approved semaglutide typically requires a BMI of 27+ with weight-related conditions or 30+ without, PlexusDx patients are evaluated individually by licensed providers. If your medical history and weight loss goals align with clinical evidence for GLP-1 therapy, you may qualify for compounded semaglutide starting at $149/month, regardless of strict BMI cutoffs.
What happens if I have type 2 diabetes and want to start semaglutide for weight loss?
Semaglutide is highly effective for patients with type 2 diabetes, improving both weight and blood sugar control. However, your existing diabetes medications—especially insulin or sulfonylureas—may need dosing adjustments to prevent low blood sugar. PlexusDx providers coordinate closely with your primary care physician to manage these interactions safely.
Is compounded semaglutide from PlexusDx the same as brand-name Ozempic?
PlexusDx semaglutide is compounded by licensed 503A pharmacies using pharmaceutical-grade ingredients, delivering the same active compound as Ozempic but at a lower cost—starting at $149/month with no insurance required and HSA/FSA eligibility. While not FDA-approved under brand names, compounded semaglutide meets strict quality and potency standards.
What are the most common side effects, and who should avoid them?
The most frequent side effects are nausea, constipation, and reduced appetite—usually mild and temporary. However, anyone with a personal or family history of medullary thyroid cancer, MEN2 syndrome, severe pancreatitis, or severe gastroparesis should not use semaglutide. PlexusDx screens for all contraindications before approval.
How can the Precision Peptide Genetic Test help me choose between semaglutide and other GLP-1 options?
PlexusDx's Precision Peptide Genetic Test ($99) maps your GLP1R and GIPR variants—key receptors that determine how well you respond to semaglutide versus tirzepatide. Patients with certain genetic profiles show stronger response to one therapy over another, helping your provider select your best-fit medication from day one rather than through trial and error.
Related Reading
Pricing and availability current as of June 2026. Compounded GLP-1 medications are not FDA-approved drug products; they are prepared by licensed compounding pharmacies under federal compounding regulations. Compounded semaglutide and tirzepatide are not the same as Wegovy, Ozempic, Zepbound, or Mounjaro. This article is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Return to the PlexusDx Education Hub for more evidence-based resources on GLP-1 therapy, metabolic health, and personalized weight management.
Medical and Editorial Standards
Medical review process: This article was reviewed for medical accuracy, scientific clarity, evidence alignment, and appropriate discussion of genetics, medications, supplements, biomarkers, and health-related claims.
Sources and evidence: PlexusDx educational content is developed using peer-reviewed research, clinical literature, reputable medical references, and, where applicable, public health or regulatory guidance.
Commercial transparency: PlexusDx offers genetic testing, blood biomarker testing, personalized supplement recommendations, and related precision wellness services. Product mentions are intended to help readers understand available options and should not be interpreted as medical advice.
Important disclaimer: PlexusDx educational content is for informational purposes only and should not be used as a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making decisions about medications, supplements, genetic testing, lab testing, or health-related care.
Share:
How to Give Yourself an Injection of Semaglutide: A Comprehensive Guide
Do You Lose Fat or Muscle on Ozempic? Understanding Body Composition During Weight Loss